Published in Hepatology on January 05, 2011
Introduction to the revised American Association for the Study of Liver Diseases Position Paper on acute liver failure 2011. Hepatology (2012) 2.31
Steroid use in acute liver failure. Hepatology (2013) 2.23
Acute and acute severe (fulminant) autoimmune hepatitis. Dig Dis Sci (2012) 2.08
Recent developments in acute liver failure. Best Pract Res Clin Gastroenterol (2012) 1.05
Ongoing activation of autoantigen-specific B cells in primary biliary cirrhosis. Hepatology (2014) 0.98
Antimitochondrial antibody heterogeneity and the xenobiotic etiology of primary biliary cirrhosis. Hepatology (2013) 0.96
Update on Autoimmune Hepatitis. J Clin Transl Hepatol (2015) 0.89
Two-year outcomes in initial survivors with acute liver failure: results from a prospective, multicentre study. Liver Int (2014) 0.89
Antimitochondrial antibody recognition and structural integrity of the inner lipoyl domain of the E2 subunit of pyruvate dehydrogenase complex. J Immunol (2013) 0.82
Autoimmune hepatitis, one disease with many faces: etiopathogenetic, clinico-laboratory and histological characteristics. World J Gastroenterol (2015) 0.81
Two sides of one coin: massive hepatic necrosis and progenitor cell-mediated regeneration in acute liver failure. Front Physiol (2015) 0.80
Challenges in the diagnosis and management of autoimmune hepatitis. Can J Gastroenterol (2013) 0.79
Prevalence and Significance of Autoantibodies in Children with Acute Liver Failure. J Pediatr Gastroenterol Nutr (2016) 0.78
Nationwide longitudinal analysis of acute liver failure in taiwan. Medicine (Baltimore) (2014) 0.78
Global Disparities and Their Implications in the Occurrence and Outcome of Autoimmune Hepatitis. Dig Dis Sci (2017) 0.77
Determinants of outcome among patients with acute liver failure listed for liver transplantation in the United States. Liver Transpl (2016) 0.77
Transitioning from Idiopathic to Explainable Autoimmune Hepatitis. Dig Dis Sci (2015) 0.77
Diagnosis and Management of Autoimmune Hepatitis: Current Status and Future Directions. Gut Liver (2016) 0.77
Centrilobular zonal necrosis as a hallmark of a distinctive subtype of autoimmune hepatitis. Eur J Gastroenterol Hepatol (2016) 0.77
The role of hepatitis E virus infection in adult Americans with acute liver failure. Hepatology (2016) 0.75
Severe Acute Hepatocellular Injury Attributed to OxyELITE Pro: A Case Series. Dig Dis Sci (2016) 0.75
Clinical characteristics and corticosteroid therapy in patients with autoimmune-hepatitis-induced liver failure. World J Gastroenterol (2014) 0.75
Autoimmune hepatitis: current challenges and future prospects. Clin Exp Gastroenterol (2017) 0.75
Efforts at making the diagnosis of acute-onset autoimmune hepatitis. Hepatology (2011) 0.75
Autoimmune acute liver failure. Hepatology (2011) 0.75
Are There Any Etiology-Based Specific Findings of Imaging Appearance in Acute Liver Failure? Dig Dis Sci (2015) 0.75
Recent advances in management of acute liver failure. Indian J Crit Care Med (2015) 0.75
The Fingerprint of Antimitochondrial Antibodies and the Etiology of Primary Biliary Cholangitis. Hepatology (2017) 0.75
An elderly female with rib osteolytic lesion after recovery from fulminant liver failure induced by acute-onset autoimmune hepatitis. Clin Case Rep (2015) 0.75
Treatment Response and Outcome with Two Different Prednisolone Regimens in Autoimmune Hepatitis. Dig Dis Sci (2017) 0.75
Skin Manifestations Associated with Autoimmune Liver Diseases: a Systematic Review. Clin Rev Allergy Immunol (2017) 0.75
International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol (1999) 9.11
Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology (2008) 6.35
Chronic hepatitis. An update on terminology and reporting. Am J Surg Pathol (1995) 4.68
The management of fulminant hepatic failure. Prog Liver Dis (1970) 4.37
Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology (1972) 4.29
Banff schema for grading liver allograft rejection: an international consensus document. Hepatology (1997) 3.22
Innate immune system plays a critical role in determining the progression and severity of acetaminophen hepatotoxicity. Gastroenterology (2004) 2.26
Antimitochondrial antibodies in acute liver failure: implications for primary biliary cirrhosis. Hepatology (2007) 1.93
Diagnostic value and utility of the simplified International Autoimmune Hepatitis Group (IAIHG) criteria in acute and chronic liver disease. Hepatology (2009) 1.77
Etiologies of acute liver failure. Semin Liver Dis (2008) 1.54
Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. Clin Gastroenterol Hepatol (2004) 1.48
Autoimmune hepatitis: clinical challenges. Gastroenterology (2001) 1.37
B cell gene signature with massive intrahepatic production of antibodies to hepatitis B core antigen in hepatitis B virus-associated acute liver failure. Proc Natl Acad Sci U S A (2010) 1.26
A novel histological lesion in glucocorticoid-responsive chronic hepatitis. Gastroenterology (1997) 1.25
The significance of autoantibodies and immunoglobulins in acute liver failure: a cohort study. J Hepatol (2007) 1.16
Autoimmune hepatitis with centrilobular necrosis. Am J Surg Pathol (2004) 1.02
B cell activation state-governed formation of germinal centers following viral infection. J Immunol (2007) 1.00
"Silent" presentation of veno-occlusive disease after liver transplantation as part of the process of cellular rejection with endothelial predilection. Hepatology (1999) 0.98
Recent-onset autoimmune hepatitis. Biopsy findings and clinical correlations. Am J Surg Pathol (1995) 0.97
Centrilobular necrosis in autoimmune hepatitis: a histological feature associated with acute clinical presentation. J Clin Pathol (2006) 0.95
Acute autoimmune hepatitis presenting with centrizonal liver disease: case report and review of the literature. Am J Gastroenterol (2002) 0.94
Autoantibodies to hepatic microsomal carboxylesterase in halothane hepatitis. Lancet (1993) 0.94
Centrilobular necrosis after orthotopic liver transplantation: a longitudinal clinicopathologic study in 71 patients. Liver Transpl Surg (1995) 0.94
Auxiliary transplantation for acute liver failure: Histopathological study of native liver regeneration. Liver Transpl (2008) 0.94
Autoimmune hepatitis: a histological variant associated with prominent centrilobular necrosis. Gut (1997) 0.89
Clinicopathologic features of the severe form of acute type 1 autoimmune hepatitis. Clin Gastroenterol Hepatol (2007) 0.89
Central venulitis in liver allografts: considerations of differential diagnosis. Hepatology (2001) 0.86
Significance of central perivenulitis in pediatric liver transplantation. Am J Surg Pathol (2008) 0.85
Clinicopathologic spectrum of massive and submassive hepatic necrosis in infants and children. Hum Pathol (2009) 0.83
Central perivenulitis: a common and potentially important finding in late posttransplant liver biopsies. Liver Transpl (2008) 0.82
Fibrous obliterative lesions of veins contribute to progressive fibrosis in chronic liver allograft rejection. Hepatology (2000) 0.82
Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med (2011) 19.01
A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology (2003) 16.40
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med (2009) 14.31
Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med (2002) 11.38
Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology (2005) 10.66
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med (2008) 9.33
Telaprevir for previously treated chronic HCV infection. N Engl J Med (2010) 8.33
Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA (2012) 7.62
Primary biliary cirrhosis. N Engl J Med (2005) 7.59
Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet (2006) 7.53
Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology (2008) 6.15
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology (2010) 6.14
Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology (2002) 5.48
Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology (2008) 5.45
Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology (2003) 5.40
Primary biliary cirrhosis. Hepatology (2009) 5.35
AASLD position paper: the management of acute liver failure. Hepatology (2005) 5.09
Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell (2012) 4.98
Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology (2009) 4.90
Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection. Proc Natl Acad Sci U S A (2006) 4.84
Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology (2003) 4.69
Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology (2004) 4.27
A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology (2008) 4.23
Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome. Am J Med (2008) 4.07
Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology (2005) 3.95
Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology (2009) 3.88
Measurement of serum acetaminophen-protein adducts in patients with acute liver failure. Gastroenterology (2006) 3.85
Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med (2007) 3.72
Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology (2009) 3.50
The plasma lipidomic signature of nonalcoholic steatohepatitis. Hepatology (2009) 3.48
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials (2004) 3.46
Detection of hepatocellular carcinoma at advanced stages among patients in the HALT-C trial: where did surveillance fail? Am J Gastroenterol (2013) 3.41
Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology (2010) 3.35
Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum (2002) 3.30
Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study. Hepatology (2006) 3.18
Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J Hepatol (2005) 3.18
Genome-wide meta-analyses identify three loci associated with primary biliary cirrhosis. Nat Genet (2010) 3.15
Screening for Wilson disease in acute liver failure: a comparison of currently available diagnostic tests. Hepatology (2008) 3.04
Nomenclature of the finer branches of the biliary tree: canals, ductules, and ductular reactions in human livers. Hepatology (2004) 3.00
Hepatocyte telomere shortening and senescence are general markers of human liver cirrhosis. FASEB J (2002) 2.96
NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology (2002) 2.96
Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol (2010) 2.96
Detection of acetaminophen protein adducts in children with acute liver failure of indeterminate cause. Pediatrics (2006) 2.96
The impact of fat distribution on the severity of nonalcoholic fatty liver disease and metabolic syndrome. Hepatology (2007) 2.94
A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol (2004) 2.84
Association between high-normal levels of alanine aminotransferase and risk factors for atherogenesis. Gastroenterology (2013) 2.82
Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology (2008) 2.80
Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma. Cancer Res (2005) 2.78
Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med (2011) 2.72
JNK1 but not JNK2 promotes the development of steatohepatitis in mice. Hepatology (2006) 2.70
Interleukin 6/gp130-dependent pathways are protective during chronic liver diseases. Hepatology (2003) 2.68
Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment. Gastroenterology (2004) 2.64
Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol (2005) 2.63
Complications and use of intracranial pressure monitoring in patients with acute liver failure and severe encephalopathy. Liver Transpl (2005) 2.63
Endoscopic Transpapillary Gallbladder Stent Placement Is Safe and Effective in High-Risk Patients Without Cirrhosis. Dig Dis Sci (2014) 2.62
Unrecognized acetaminophen toxicity as a cause of indeterminate acute liver failure. Hepatology (2011) 2.61
Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective. J Hepatol (2010) 2.58
Humanized mice for modeling human infectious disease: challenges, progress, and outlook. Cell Host Microbe (2009) 2.58
Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study. J Hepatol (2007) 2.58
Effectiveness of hepatocellular carcinoma surveillance in patients with cirrhosis. Cancer Epidemiol Biomarkers Prev (2012) 2.57
Myeloid-derived suppressor cells in inflammatory bowel disease: a new immunoregulatory pathway. Gastroenterology (2008) 2.56
Prospective biopsy-controlled evaluation of cell death biomarkers for prediction of liver fibrosis and nonalcoholic steatohepatitis. Hepatology (2011) 2.49
Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology (2010) 2.47
Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology (2009) 2.45
Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology (2008) 2.44
Therapeutic hypothermia in acute liver failure: a multicenter retrospective cohort analysis. Liver Transpl (2015) 2.44
Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology (2004) 2.44
The prevalence and risk factors associated with esophageal varices in subjects with hepatitis C and advanced fibrosis. Gastrointest Endosc (2006) 2.43
Myeloid derived suppressor cells in human diseases. Int Immunopharmacol (2011) 2.43
Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test. Hepatology (2009) 2.40
The multi-dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregivers. Am J Gastroenterol (2011) 2.37
Tumor necrosis factor-induced toxic liver injury results from JNK2-dependent activation of caspase-8 and the mitochondrial death pathway. J Biol Chem (2006) 2.36
Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study. BMJ (2012) 2.32
Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology (2010) 2.30
Liver autoimmunity triggered by microbial activation of natural killer T cells. Cell Host Microbe (2008) 2.30
Development of an accurate index for predicting outcomes of patients with acute liver failure. Gastroenterology (2012) 2.26
Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology (2010) 2.26
Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology (2011) 2.25
Steroid use in acute liver failure. Hepatology (2013) 2.23
MicroRNAs play a role in spontaneous recovery from acute liver failure. Hepatology (2014) 2.23
Deletion of IKK2 in hepatocytes does not sensitize these cells to TNF-induced apoptosis but protects from ischemia/reperfusion injury. J Clin Invest (2005) 2.20
Anti-mitochondrial antibodies and primary biliary cirrhosis in TGF-beta receptor II dominant-negative mice. J Immunol (2006) 2.18
Intensive care of patients with acute liver failure: recommendations of the U.S. Acute Liver Failure Study Group. Crit Care Med (2007) 2.17